RxDoctor Payments DataLook up a doctor →

Rachel Person, APRN

Dermatology · Omaha, NENPI 1841673738

Payments from drug & device makers

$97,861in general payments, 2019–2025

Across 775 payments — averaging $126.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$70K
  • Amgen$19K
  • AbbVie$2K
  • Pfizer$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Incyte Corporation$873
  • plus $4K from 15 others

What the payments were for

  • Speaking & faculty fees$82,24484%
  • Travel & lodging$4,0964%
  • Food & beverage$11,28612%
  • Education$2340%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,861 in reported general payments places this provider in the 90th percentile of 68 dermatology providers in Nebraska.

See all dermatology providers in Nebraska

Medicare billing

Part B allowed, 2024
$155,172
Medicare patients
882
Services billed
3,951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab51$215,432
Cimzia (2 Pack)Certolizumab Pegol13$146,140
OtezlaApremilast22$114,353
Clobetasol Propionate120$6,436
Ketoconazole189$2,374
MethotrexateMethotrexate Sodium75$1,789
Fluorouracil28$1,721
Clindamycin Phosphate47$1,717
Metronidazole22$1,550
Triamcinolone Acetonide95$485
Hydroxychloroquine Sulfate18$481
Mupirocin76$443
Spironolactone21$386
Hydrocortisone61$251
Nystatin16$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$567$146,14013 claims
AmgenOtezla$19,172$114,35322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 dermatology providers in Nebraska.

Other dermatology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →